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analysis was to develop two cost effectiveness models taking into account the 
new management of the treatment of AF and VTE in France. The clinical and cost 
benefits of VKA (with/without the use of a PAS) has been evaluated versus new 
oral anticoagulants (NOAC): dabigatran, rivaroxaban and apixaban. Methods: 
A Markov model was built for the treatment of AF and a decision tree for the 
treatment and prevention of VTE. In the VKA arms, both models integrate the pos-
sibility to adjust the percentage of time spent by patients within INR therapeutic 
range. In the VTE model, outcomes were expressed in cost per avoided event 
whereas in the AF model in cost per QALY. Results: In both models, apixaban is 
the strategy producing the least thromboembolic and hemorrhagic events whereas 
AVK strategies are the cheapest treatments (2 to 2.5 times less than NOAC treat-
ments). The use of the software for the treatment and prevention of VTE allows 
to save € 3,192 per avoided event and for the AF treatment € 7,557 per extra QALY 
gained and € 6,688 per avoided event. ConClusions: Based on French guide-
lines for economic evaluation, apixaban and VKA + PAS are efficient strategies 
in AF.
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objeCtives: As new therapies for chronic heart failure with reduced ejection 
fraction (HFrEF) emerge, health technology assessments (HTAs) will require cost-
effectiveness analyses to inform decision making. The objective was to develop 
a model framework for evaluating the cost-effectiveness of LCZ696, a novel oral 
therapy proposed for the treatment of HFrEF. Methods: A systematic literature 
review was performed. Searches were conducted in MEDLINE, EMBASE, EconLit, and 
Cochrane Library databases, with supplementary hand searching of conferences and 
HTA websites. Of 63 distinct analyses identified, 33 used decision-analytic models. 
Structures were most commonly described as Markov models (n= 27), but meth-
ods employed were heterogeneous. The health states most frequently employed 
were ‘alive’ and ‘dead’, with outcomes such as hospitalization or New York Heart 
Association (NYHA) class distribution most commonly considered within the ‘alive’ 
state. Results: A 2-state Markov model with ‘alive’ and ‘dead’ states was developed 
using three multivariate regression models to predict the risks of mortality, hospi-
talisation and the trajectory of health-related quality of life over time within the 
‘alive’ state. NYHA class was not used as a basis for health states, as the extrapola-
tion of clinical improvements beyond the observed data was considered clinically 
implausible. Parametric survival models, negative binomial models and multilevel 
models are used to predict mortality, hospitalisation, and HRQL, respectively, allow-
ing extrapolation to a lifetime time horizon. The model of HRQL attempts to cap-
ture the effects of baseline characteristics, hospitalisation, adverse events and time 
on EQ-5D. Clinical experts were consulted to validate the regression models and 
their respective predictions. ConClusions: The new framework employs similar 
methods to decision analytic models developed previously in heart failure, however 
models health-related quality of life as a function of time directly, thereby providing 
a parsimonious approach with improved clinical plausibility compared to other 
model structures in the literature.
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objeCtives: Venous thromboembolism (VTE) which comprises deep vein throm-
bosis (DVT) and pulmonary embolism (PE) is associated with a significant health-
care burden. Currently, the standard of care is parenteral low molecular weight 
heparin (enoxaparin) plus warfarin. Rivaroxaban is an oral anticoagulant that 
does not require dose adjustment or routine coagulation monitoring, bringing 
an important advantage for the treatment of VTE. The EINSTEIN clinical pro-
gram of rivaroxaban showed that, overall, hospitalized patients who received 
initial treatment with rivaroxaban for DVT and PE had a significantly shorter 
length of stay compared to patients who received enoxaparin/VKA. Therefore, 
the aim of this study was to compare the direct costs of treatment with rivar-
oxaban versus enoxaparin/warfarin. Methods: A cost-minimization analysis 
(CMA) was chosen once the EINSTEN program showed that rivaroxaban is non-
inferior to enoxaparin/VKA with regards to efficacy for treatment of VTE being 
possible to consider that there is no difference in outcomes. Perspective was 
from the Brazilian private healthcare system and time horizon was one year. 
Costs related to hospitalization, outpatient management and adverse events 
were obtained by micro-costing approach and resource use captured from lit-
erature and expert panel. Costs were expressed in 2015 prices and exchange rate 
used was $1.00USD= 3.00BRL. Results: Rivaroxaban use resulted less expen-
sive than enoxaparin+warfarin in the treatment of VTE. Estimated total cost of 
treatment for one patient with VTE is $2,079 with rivaroxaban and $2,716 with 
enoxaparin+warfarin. The greater difference in costs was for treatment of PE, which 
was $688.57 less for rivaroxaban. For DVT treatment, estimated savings for rivar-
oxaban was $561.46. Robustness of the model was tested in a deterministic univar-
iate sensitivity analysis in which all results remained cost saving. ConClusions: 
Rivaroxaban is a cost-saving alternative compared to the current practice for 
the treatment of VTE under the perspective of the Brazilian private healthcare 
system.
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objeCtives: In-situ tissue-engineering provides a promising method to cre-
ate living heart valves with the potential to grow, repair and last a lifetime. The 
objective of the present study is to develop a conceptual model (CM) that can be 
used to investigate the requirements for tissue-engineered heart valves (TEHV) to 
become cost-effective compared to current surgical and transcatheter heart valve 
substitutes (HVS). Methods: The development of the CM was based on recom-
mendations from the ISPOR-SMDM Modeling Good Research Practices Task Force-2. 
After scoping the decision problem, a draft CM was developed based on clinical 
guidelines and discussion within a small workgroup. This model was compared 
with existing models for cost-effectiveness of HVS, found by systematic literature 
search. It was further discussed with a Delphi panel of cardio-thoracic surgeons, 
cardiologists and a biomedical scientist (n= 10). Delphi panelists were first inter-
viewed individually to discuss the CM structure. Thereafter, they completed online 
surveys in order to reach consensus between panelists. Results: Health states 
included in the CM are ‘alive without complications’, cerebrovascular accident, 
myocardial infarction, vascular complication, bleeding, acute kidney injury, atrial 
fibrillation, pacemaker implantation, prosthetic valve dysfunction, prosthetic 
valve thrombosis, prosthetic valve endocarditis, ‘alive after complications’ and 
dead. Predictors of transition probabilities between the health states are included; 
age, gender, NYHA functional class, left ventricular function, renal impairment, 
and diabetes. Relevant outcome measures included health-related quality of 
life, event occurrence, event-free survival, mortality and costs. ConClusions: 
The CM provides the foundation of a microsimulation model that will be used 
to estimate the cost-effectiveness of TEHV compared with current HVS. The 
results will be used to inform stakeholders about the requirements for TEHV to 
become cost-effective. This information can help bio-tech companies to decide 
about further development of TEHV, focus on the most promising target groups, 
set realistic performance-price goals, and design and manage a reimbursement 
strategy.
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objeCtives: The World Health Organization guidelines recommend that an 
increase of potassium intake reduce blood pressure in adults. In addition, inter-
vention with vitamin B2 has been shown to lower blood pressure in patients with 
genotype, specifically in hypertensive patients with premature cardiovascular dis-
ease (CVD) homozygous for the 677C→ T polymorphism (TT genotype) in the gene 
encoding for the enzyme methylenetetrahydrofolate reductase. In the Chinese 
northern region, the prevalence of this TT genotype was estimated to be 35% of the 
population. Furthermore, 26% of adults are hypertensive and 20% adults will experi-
ence a CVD episode.This study aims to evaluate the impact of increased intake of 
potassium and vitamin B2 have on blood pressure, CVD events and quality-of-life 
among Chinese adults older than 45 years old. Furthermore this study assesses the 
costs and cost-effectiveness of achieving this impact via the consumption of a forti-
fied milk product. Methods: An analytical decision model was used to quantify 
and compare three strategies against the current intake of the at-risk-population: 1) 
Increased potassium intake level 2) Increased vitamin B2 intake level 3) Combined 
increased vitamin B2 and potassium intake levels. The effectiveness of these strate-
gies in incrementing vitamin B2 and potassium were determined by patient level 
data and the Framingham methodology. All costs and epidemiological data were 
collected from the literature. Results: All strategies led to statistically significant 
health outcomes due to the preventive effect of increased intake of potassium and 
vitamin B2 also resulting in a significant Quality Adjusted Life Years gain over the 
baseline. Each strategy is shown to be cost-effective or highly cost-effective with 
the largest effect being the combined increased intake of potassium and vitamin 
B2. ConClusions: The strategy of the combined increased intake of vitamin B2 
and potassium is highly cost-effective thereby preventing CVD events and saving 
costs to the health system.
PCV117
CliNiCAl ANd eCoNoMiC iMPACts of the use of A PresCriPtioN 
AssistANCe softwAre for VitAMiN k ANtAgoNist treAtMeNt iN freNCh 
MANAgeMeNt of AtriAl fibrillAtioN ANd VeNous throMboeMboliC 
eVeNts
Sivignon M1, Roze S1, Murphy C2, Tisseau A2
1HEVA HEOR Sarl, Lyon, France, 2Merck Serono Sas, Lyon, France
objeCtives: Vitamin K Antagonist (VKA) have traditionally been the main treat-
ment for thromboembolic event prevention in atrial fibrillation (AF) and for the 
treatment of venous and pulmonary thromboembolic events (VTE) and the pre-
vention of their relapses. A close patient monitoring with the determination of 
the INR (International Normalized Ratio) is needed during the AVK treatment, to 
avoid adverse thrombotic or hemorrhagic events. The improvement of the time 
spent in the therapeutic range (TTR), depending on INR results, has previously 
been studied in France with the use of a prescription assistance software (PAS). 
The use of this PAS improves the TTR from 58.46% to 71.79%. The objective of the 
